A day after the Pharmaceutical Research and Manufacturers of America (PhRMA) and HHS proposed policies for including drug price information in direct-to-consumer advertising, Johnson & Johnson started big pharma’s slate of third quarter earnings calls by voicing support of both approaches but, not surprisingly, preferring PhRMA’s voluntary approach to transparency.
HHS Secretary Alex Azar outlined a Centers for Medicare and Medicaid proposal Oct. 15 that would require drug makers to...





